Equities

Solventum Corp

Solventum Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)71.61
  • Today's Change0.80 / 1.13%
  • Shares traded1.62m
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 26 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform0
Hold9
Sell1
Strong Sell0

Share price forecast in USD

The 7 analysts offering 12 month price targets for Solventum Corp have a median target of 73.00, with a high estimate of 82.00 and a low estimate of 62.89. The median estimate represents a 1.94% increase from the last price of 71.61.
High14.5%82.00
Med1.9%73.00
Low-12.2%62.89

Earnings history & estimates in USD

On Nov 07, 2024, Solventum Corp reported 3rd quarter 2024 earnings of 1.64 per share.
Average growth rate-9.94%
More ▼

Revenue history & estimates in USD

Solventum Corp had 3rd quarter 2024 revenues of 2.08bn. This bettered the 2.06bn consensus of the 7 analysts covering the company. The same period last year the company did not report revenues.
Average growth rate+1.64%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.